Article

Potential retinal disease treatments to be presented at ARVO

Preclinical results for two new compounds (Sirion) that may be used for the treatment of retinal diseases will be presented during the 2008 annual meeting of the Association for Research in Vision and Ophthalmology.

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
Related Content
Melt Pharmaceuticals doses final patient in phase 3 trial of MELT-300
October 11th 2024

Melt Pharmaceuticals doses final patient in phase 3 trial of MELT-300

EyePod: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD
October 11th 2024

Innovation Series: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD

Nanoscope to submit BLA for MCO-010 to treat retinitis pigmentosa
October 10th 2024

Nanoscope to submit BLA for MCO-010 to treat retinitis pigmentosa

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

MJH Life Sciences acquires EnVision Summit - ©dennisvdwater
October 9th 2024

MJH Life Sciences, parent of Ophthalmology Times, acquires EnVision Summit

Doheny Eye Institute ophthalmologists to present at the AAO 2024 Annual Meeting
October 9th 2024

Doheny Eye Institute ophthalmologists to present at the AAO 2024 Annual Meeting

© 2024 MJH Life Sciences

All rights reserved.